Collaborative Research Agreement Amendment 8, dated as of December 5, 2020 by and between National Taiwan University and PTC Therapeutics GT, Inc

EX-10.51 3 ptct-20201231ex10512e2d9.htm EX-10.51

Exhibit 10.51

Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.

Collaborative Research Agreement Amendment No. 8

This Amendment No. 8 is made and entered into as of December 5, 2020 (the “Amendment 8 Effective Date") to that certain Collaborative Research Agreement dated September 30, 2015 (as amended, the “Agreement”) by and between National Taiwan University at No. 1, Sec. 4, Roosevelt Road, Taipei, 10617 Taiwan (R.O.C) (hereinafter “NTU”) and PTC Therapeutics GT, Inc. (formerly Agilis Biotherapeutics), a Delaware corporation duly organized under law and having an address at 6 Kimball Lane, Suite 320, Lynnfield, Massachusetts, 01940 USA (hereinafter “COMPANY”). Capitalized terms herein shall have the meaning ascribed to them in the Agreement. To the extent of any conflict with the prior amendments to the Agreement, this Amendment 7supersedes the prior amendments.

WHEREAS, the COMPANY and NTU previously amended the agreement via Amendments 1 through 7. In the previous amendments, the COMPANY and NTU agreed to a continue the active studies, including active Phase IIb Protocol studies and related research through March 31, 2021; and an additional research project and corresponding increases in the budget for [**].  

NOW, THEREFORE, the COMPANY and NTU wish to further amend the Agreement as follows:


a. Principal Investigator. NTU designates Professor Yin-Hsiu Chien, an employee of NTU as the principal investigator (“Principal Investigator”). The parties understand and acknowledge that Principal Investigator is conducting the Study at NTU and not as a separate party to this Agreement. NTU shall ensure that the Principal Investigator abides by the provisions in this Agreement.

b.Additional Research Budget (Amendment No. 8).  During January 1, 2021 through March 31, 2021, the budget shall be increased by [**] U.S. Dollars (USD$ [**] ) which amount is inclusive of NTU’s fees, based upon the fee schedule for the Services outlined in Attachment A. Invoices shall reflect the fees due in U.S. Dollars and shall be sent to [**], with a copy to COMPANY’s project manager. All invoices shall include the Purchase Order provided by COMPANY.

COMPANY shall pay NTU within [**] of its receipt of each invoice.

c.NTU Account Information. In order to process invoice payments promptly, COMPANY will process payments utilizing NTU’s payee information contained in the Payee Account Information Form provided in Attachment B.

2.Effect of Amendment.  As of the Amendment Effective Date, this Amendment shall amend, modify and supersede, to the extent of any inconsistencies, the provisions of the Agreement.  Except as expressly modified by this Amendment, the Agreement shall remain in full force and effect.  Capitalized terms used in this Amendment and not otherwise defined shall have the meaning ascribed to such terms in the Agreement.  As of the Amendment Effective Date, any reference to the Agreement shall be deemed a reference to the Agreement as amended by this Amendment.

3.  General Provisions.

a. Counterparts.  This Amendment may be executed in any one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.

b. Miscellaneous.  The Agreement, as amended by this Amendment, sets forth the entire understanding between and among the parties and there are no other understandings or promises, written or verbal, not

set forth herein, relating specifically to the subject matter hereof.  The Agreement, as amended by this Amendment, supersedes any prior or contemporaneous agreements with respect to the subject matter hereof.

c. Headings.  The headings and subheadings of the sections of this Amendment have been included solely for the ease of reference and do not form part of this Amendment.

IN WITNESS WHEREOF, both NTU and COMPANY have executed this Amendment 8, in duplicate originals, electronic mail of PDFs or electronic signatures, by their respective and duly authorized officers on the day and year written.



Authorized Signature

By: /s/ Matthew Klein

By: /s/ Chung-Ming Kuan

Authorized Signature

Matthew Klein, MD, MS, FACS

Chief Development Officer

Printed Name & Title

Date: 26 December 2020